Dec 11 (Reuters) - AnaptysBio ANAB.O:
ANAPTYS ANNOUNCES PHASE 2B TRIAL OF ANB032, A BTLA AGONIST, DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS IN ATOPIC DERMATITIS
ANAPTYSBIO INC: ANTICIPATE TOP-LINE PHASE 2B DATA IN RHEUMATOID ARTHRITIS IN FEBRUARY 2025
ANAPTYSBIO INC - ANB032 AD TRIAL AND ALL FURTHER INVESTMENT WILL BE DISCONTINUED
ANAPTYSBIO INC - ANB032 WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED
ANAPTYSBIO INC - YEAR-END 2024 CASH ABOUT $415 MILLION
Source text: ID:nGNXbd61Yl
Further company coverage: ANAB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.